← Back to Clinical Trials
Recruiting NCT06302127

NCT06302127 County Medical Community-based, Cardiovascular Risk Stratified Integrated Care Model: a Pragmatic Cluster Randomised Control Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06302127
Status Recruiting
Phase
Sponsor Peking University
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 2,560 participants
Start Date 2024-05-20
Primary Completion 2025-10-20

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Team-based careRisk-stratified care pathwayStrengthened health education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,560 participants in total. It began in 2024-05-20 with a primary completion date of 2025-10-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this cluster randomized trial is to evaluate the effectiveness of the RISIMA model based on an integrated county healthcare consortium implemented by multi-level family health teams (FHTs)on patients with diabetes and/or hypertension, including CVD risk assessment, treatment, and management.

Eligibility Criteria

Inclusion Criteria: 1. Aged between 40 and 70 years old; 2. Patients with hypertension or diabetes; 3. Permanent residents of the county where the research is conducted; 4. Already signed up with the family doctor team in the township where the research is located. Exclusion Criteria: 1. Unable to independently carry out the interventions required for the study; 2. Residing far from the village or township health center where the research is located, making it difficult to cooperate with visits; 3. Patients who refuse to participate; 4. Patients with comorbidities such as cancer that may interfere with the study visits or intervention effects; 5. Pregnant or lactating women

Contact & Investigator

Central Contact

Jin Prof. Xu, PhD

✉ xujin@hsc.pku.edu.cn

📞 0086-82805701

Frequently Asked Questions

Who can join the NCT06302127 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06302127 currently recruiting?

Yes, NCT06302127 is actively recruiting participants. Contact the research team at xujin@hsc.pku.edu.cn for enrollment information.

Where is the NCT06302127 trial being conducted?

This trial is being conducted at Sanming, China, Liuzhou, China, Liuzhou, China.

Who is sponsoring the NCT06302127 clinical trial?

NCT06302127 is sponsored by Peking University. The trial plans to enroll 2,560 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology